Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Page 1
Nonalcoholic fatty liver disease burden - Switzerland 2018-2030.
Goossens N, Bellentani S, Cerny A, Dufour JF, Jornayvaz FR, Mertens J, Moriggia A, Muellhaupt B, Negro F, Razavi H, Semela D, Estes C. Goossens N, et al. Among authors: bellentani s. Swiss Med Wkly. 2019 Dec 17;149:w20152. doi: 10.4414/smw.2019.20152. eCollection 2019 Dec 16. Swiss Med Wkly. 2019. PMID: 31846507 Free article.
A Markov model was built to quantify fibrosis progression among the NAFLD and NASH populations, and predict disease burden up to 2030. Long-term trending of NAFLD prevalence was based on changes in the prevalence of adult obesity. ...
A Markov model was built to quantify fibrosis progression among the NAFLD and NASH populations, and predict disease burden up to 2030. Long- …
A "systems medicine" approach to the study of non-alcoholic fatty liver disease.
Petta S, Valenti L, Bugianesi E, Targher G, Bellentani S, Bonino F; Special Interest Group on Personalised Hepatology of the Italian Association for the Study of the Liver (AISF); Special Interest Group on Personalised Hepatology of Italian Association for Study of Liver AISF. Petta S, et al. Among authors: bellentani s. Dig Liver Dis. 2016 Mar;48(3):333-42. doi: 10.1016/j.dld.2015.10.027. Epub 2015 Nov 14. Dig Liver Dis. 2016. PMID: 26698409 Free article. Review.
Based on this premise and in light of recent findings, the complex mechanisms involved in the pathology of fatty liver and their impact on the short- and long-term clinical outcomes of cardiovascular, metabolic liver diseases associated with steatosis are presented in this …
Based on this premise and in light of recent findings, the complex mechanisms involved in the pathology of fatty liver and their impact on t …
Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD).
Scaglioni F, Marino M, Ciccia S, Procaccini A, Busacchi M, Loria P, Lonardo A, Malavolti M, Battistini NC, Pellegrini M, Carubbi F, Bellentani S. Scaglioni F, et al. Among authors: bellentani s. Clin Res Hepatol Gastroenterol. 2013 Sep;37(4):353-8. doi: 10.1016/j.clinre.2012.10.009. Epub 2012 Dec 27. Clin Res Hepatol Gastroenterol. 2013. PMID: 23273500 Clinical Trial.
Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells.
Neuman MG, Shear NH, Bellentani S, Tiribelli C. Neuman MG, et al. Among authors: bellentani s. Gastroenterology. 1998 Jul;115(1):157-66. doi: 10.1016/s0016-5085(98)70377-4. Gastroenterology. 1998. PMID: 9649471
Tauroursodeoxycholic acid (TUDCA) and ursodeoxycholic acid (UDCA) were shown to reduce cytotoxicity. Long-term EtOH exposure leads to immunoregulatory and detoxification impairment. ...
Tauroursodeoxycholic acid (TUDCA) and ursodeoxycholic acid (UDCA) were shown to reduce cytotoxicity. Long-term EtOH exposure leads to …
Effect of ursodeoxycholic acid treatment on alanine aminotransferase and gamma-glutamyltranspeptidase serum levels in patients with hypertransaminasemia. Results from a double-blind controlled trial.
Bellentani S, Tabarroni G, Barchi T, Ferretti I, Fratti N, Villa E, Manenti F. Bellentani S, et al. J Hepatol. 1989 Jan;8(1):7-12. doi: 10.1016/0168-8278(89)90155-4. J Hepatol. 1989. PMID: 2564011 Clinical Trial.
This decrease was significantly different from the spontaneous 10% decrease of the ALT and gamma-GT levels observed in the placebo group. 3 months after suspension of therapy a rebound of both ALT and gamma-GT to values comparable to the basal ones or even higher was found only i …
This decrease was significantly different from the spontaneous 10% decrease of the ALT and gamma-GT levels observed in the placebo group. 3 …
Effect of tauroursodeoxycholate feeding, with or without taurine supplementation on hepatic bile acids and cholesterol metabolism in the hamster.
Bellentani S, Bosisio E, Pecorari M, De Fabiani E, Cordoma P, Crestani M, Manenti F. Bellentani S, et al. Pharmacol Res Commun. 1987 May;19(5):327-39. doi: 10.1016/0031-6989(87)90070-1. Pharmacol Res Commun. 1987. PMID: 3628457
This study reports the effect of short-term tauroursodeoxycholic acid (TUDCA) and of TUDCA with addition of taurine on the lipid composition of gallbladder bile, on cholesterol and bile acid synthesis and intestinal excretion, in the female hamsters. ...
This study reports the effect of short-term tauroursodeoxycholic acid (TUDCA) and of TUDCA with addition of taurine on the lipid comp …
Study of the long-term effects of selective biliary obstruction (SBO).
Bellentani S, Ferrari A, Villa E, Manenti F. Bellentani S, et al. Res Exp Med (Berl). 1981;178(3):229-35. doi: 10.1007/BF01851011. Res Exp Med (Berl). 1981. PMID: 6262890
Choosing some markers of cholestasis and some other markers of various cytoplasmic organelles, we studied the long-term effects that occur in serum and in total liver homogenate of selectively obstructed rats as compared to controls. ...
Choosing some markers of cholestasis and some other markers of various cytoplasmic organelles, we studied the long-term effects that …